TIDMMED

RNS Number : 1769K

Medaphor Group PLC

12 December 2018

The information contained within this announcement (the "Announcement") is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this Announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

MedaPhor Group plc

("MedaPhor" or the "Company")

Results of Open Offer

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, is pleased to announce that further to the announcement of the Placing and Open Offer on 26 November 2018, it has conditionally raised total gross proceeds of GBP78,778 via the Open Offer.

The Open Offer closed for acceptances at 11.00 a.m. on 11 December 2018. The Company received valid acceptances from Qualifying Shareholders in respect of 926,801 Open Offer Shares, including applications for 63,354 Open Offer Shares under the Excess Application Facility. This represents 3.8 per cent. of the maximum Open Offer Shares available under the Open Offer. Admission of the Open Offer shares is subject to passing the relevant resolutions at the General Meeting.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 26 November 2018.

Enquiries:

 
MedaPhor Group plc                  www.medaphor.com 
Stuart Gall, CEO                    Tel: +44 (0)29 2075 6534 
 Wilson Jennings, CFO 
 
Cenkos Securities - Nominated       Tel: +44 (0)20 7397 8900 
 Advisor and broker 
Mark Connelly / Cameron MacRitchie 
 (Corporate Finance) 
Michael Johnson / Julian Morse 
 (Sales) 
 
Walbrook PR                         Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com 
Anna Dunphy / Paul McManus          Mob: +44 (0)7876 741 001 / Mob: 
                                     +44 (0)7980 541 893

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROIEANAFFLDPFFF

(END) Dow Jones Newswires

December 12, 2018 02:00 ET (07:00 GMT)

Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Intelligent Ultrasound Charts.
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Intelligent Ultrasound Charts.